AIM: To evaluate the tolerance of hydroxyurea in children affected with sickle cell disease. DESIGN: Questionnaire study of French physicians likely to treat patients with sickle cell disease. Data were collected on 101 children with sickle cell disease, treated for a median of 22 months, 36 of whom were treated for more than three years. 13 children were younger than 5 years of age at inclusion. RESULTS: Hydroxyurea was stopped for medical reasons in 11 patients: 6 failures, 1 pregnancy, 1 cutaneous rash, 1 leg ulcer, 1 lupus. Acute lymphoblastic leukaemia occurred in a girl treated for 1.5 months with hydroxyurea, this short interval arguing against a causative association. One 17 year old boy had paraparesis after 8 years of treatment. CONCLUSIONS: No major short or medium term toxicity was related to hydroxyurea in this cohort of 101 children. However, the number of children treated for more than 3 years is too few to make firm conclusions on the long term tolerance of this drug.
AIM: To evaluate the tolerance of hydroxyurea in children affected with sickle cell disease. DESIGN: Questionnaire study of French physicians likely to treat patients with sickle cell disease. Data were collected on 101 children with sickle cell disease, treated for a median of 22 months, 36 of whom were treated for more than three years. 13 children were younger than 5 years of age at inclusion. RESULTS:Hydroxyurea was stopped for medical reasons in 11 patients: 6 failures, 1 pregnancy, 1 cutaneous rash, 1 leg ulcer, 1 lupus. Acute lymphoblastic leukaemia occurred in a girl treated for 1.5 months with hydroxyurea, this short interval arguing against a causative association. One 17 year old boy had paraparesis after 8 years of treatment. CONCLUSIONS: No major short or medium term toxicity was related to hydroxyurea in this cohort of 101 children. However, the number of children treated for more than 3 years is too few to make firm conclusions on the long term tolerance of this drug.
Authors: M de Montalembert; M Belloy; F Bernaudin; F Gouraud; R Capdeville; R Mardini; N Philippe; J P Jais; J Bardakdjian; R Ducrocq; M Maier-Redelsperger; J Elion; D Labie; R Girot Journal: J Pediatr Hematol Oncol Date: 1997 Jul-Aug Impact factor: 1.289
Authors: M C Walters; M Patience; W Leisenring; J R Eckman; J P Scott; W C Mentzer; S C Davies; K Ohene-Frempong; F Bernaudin; D C Matthews; R Storb; K M Sullivan Journal: N Engl J Med Date: 1996-08-08 Impact factor: 91.245
Authors: A Ferster; C Vermylen; G Cornu; M Buyse; F Corazza; C Devalck; P Fondu; M Toppet; E Sariban Journal: Blood Date: 1996-09-15 Impact factor: 22.113
Authors: P Triadou; M Maier-Redelsperger; R Krishnamoorty; A Deschamps; N Casadevall; O Dunda; R Ducrocq; J Elion; R Girot; D Labie Journal: Nouv Rev Fr Hematol Date: 1994-10
Authors: Sophie Lanzkron; John J Strouse; Renee Wilson; Mary Catherine Beach; Carlton Haywood; HaeSong Park; Catherine Witkop; Eric B Bass; Jodi B Segal Journal: Ann Intern Med Date: 2008-05-05 Impact factor: 25.391
Authors: Gaurav D Shah; Joel S Silver; Steven S Rosenfeld; Igor T Gavrilovic; Lauren E Abrey; Andrew B Lassman Journal: J Neurooncol Date: 2007-06-27 Impact factor: 4.130